One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment.

Age-related macular degeneration Brolucizumab Faricimab Switching

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
20 Apr 2024
Historique:
received: 18 12 2023
accepted: 16 04 2024
medline: 21 4 2024
pubmed: 21 4 2024
entrez: 20 4 2024
Statut: epublish

Résumé

This single-center retrospective cohort study analyzed the 1-year real-world treatment outcomes of 63 consecutive eyes (of 60 patients) with neovascular age-related macular degeneration (nAMD) that were switched from intravitreal brolucizumab (IVBr) to intravitreal faricimab (IVF) and managed on a treat-and-extend regimen with discontinuation criteria. After the switch, patients opted to continue IVF, to switch back to IVBr, or receive photodynamic therapy (PDT). Thirty-eight patients continued IVF, 16 patients were switched back to IVBr, 2 patients received PDT, and 4 patients paused treatment. Best-corrected visual acuity (BCVA), central subfield thickness (CST), subfoveal choroidal thickness (sf-CT), and injection intervals were compared immediately before and 1 year after the initial IVF. Whereas there was no change in BCVA and CST; 0 [- 0.0969 to 0.125, P = 0.58], - 1.5 [- 27.8 to 13.5, P = 0.11] µm, respectively, sf-CT decreased significantly; - 19.5 [- 45.5 to 7.75, P = 0.015] µm. The patients switched back showed no significant change in sf-CT. The injection interval extended significantly in the IVF continuation and the switch-back group (2.0 and 3.0 weeks, respectively; [P = 0.0007 and 0.0078]) in eyes with a pre-switching interval of less than 12 weeks. Faricimab shows promise as a safe and effective alternative to brolucizumab for treating nAMD.

Identifiants

DOI: 10.1038/s41598-024-59894-8 PMID: 38643252
pubmed: 38643252
doi: 10.1038/s41598-024-59894-8
pii: 10.1038/s41598-024-59894-8
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9087

Informations de copyright

© 2024. The Author(s).

Références

Rofagha, S. et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP). Ophthalmology 120, 2292–2299. https://doi.org/10.1016/j.ophtha.2013.03.046 (2013).
doi: 10.1016/j.ophtha.2013.03.046 pubmed: 23642856
Dugel, P. U. et al. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127, 72–84. https://doi.org/10.1016/j.ophtha.2019.04.017 (2020).
doi: 10.1016/j.ophtha.2019.04.017 pubmed: 30986442
Khanani, A. M. et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: The TRUCKEE study-6 month results. Eye (Lond.) https://doi.org/10.1038/s41433-023-02553-5 (2023).
doi: 10.1038/s41433-023-02553-5 pubmed: 37237234
Ito, A. et al. One-year outcomes of intravitreal brolucizumab injections in patients with polypoidal choroidal vasculopathy. Sci. Rep. 12, 7987. https://doi.org/10.1038/s41598-022-12216-2 (2022).
doi: 10.1038/s41598-022-12216-2 pubmed: 35568780 pmcid: 9107469
Matsumoto, H., Hoshino, J., Mukai, R., Nakamura, K. & Akiyama, H. Short-term outcomes of intravitreal brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy. Sci. Rep. 11, 6759. https://doi.org/10.1038/s41598-021-86014-7 (2021).
doi: 10.1038/s41598-021-86014-7 pubmed: 33762600 pmcid: 7990919
Matsumoto, H., Hoshino, J., Mukai, R., Nakamura, K. & Akiyama, H. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization. Sci. Rep. 12, 8. https://doi.org/10.1038/s41598-022-10578-1 (2022).
doi: 10.1038/s41598-022-10578-1
Nguyen, Q. D. et al. Brolucizumab: Evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology 127, 963–976. https://doi.org/10.1016/j.ophtha.2019.12.031 (2020).
doi: 10.1016/j.ophtha.2019.12.031 pubmed: 32107066
Inoda, S. et al. Incidence and risk factors of intraocular inflammation after brolucizumab treatment in Japan: A multicenter AMD study. Retina https://doi.org/10.1097/iae.0000000000004009 (2023).
doi: 10.1097/iae.0000000000004009
Pakravan, P. et al. Intraocukar inflammation incidence after intravitreal brolucizumab injection for exdative age-related macular degeneration. Retina 43, 1717–1722. https://doi.org/10.1097/iae.0000000000003862 (2023).
doi: 10.1097/iae.0000000000003862 pubmed: 37320859
Inoda, S. et al. One-year outcome of brolucizumab for neovascular age-related macular degeneration in Japanese patients. Sci. Rep. 14, 2451. https://doi.org/10.1038/s41598-024-52747-4 (2024).
doi: 10.1038/s41598-024-52747-4 pubmed: 38291120 pmcid: 10827718
Rush, R. B. & Rush, S. W. Intravitreal faricimab for aflibercept-resistant neovascular age-related macular degeneration. Clin. Ophthalmol. 16, 4041–4046. https://doi.org/10.2147/OPTH.S395279 (2022).
doi: 10.2147/OPTH.S395279 pubmed: 36532820 pmcid: 9747838
Stanga, P. E. et al. Faricimab in neovascular AMD: First report of real-world outcomes in an independent retina clinic. Eye (Lond.) https://doi.org/10.1038/s41433-023-02505-z (2023).
doi: 10.1038/s41433-023-02505-z pubmed: 36959312
Heier, J. S. et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): Two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399, 729–740. https://doi.org/10.1016/S0140-6736(22)00010-1 (2022).
doi: 10.1016/S0140-6736(22)00010-1 pubmed: 35085502
Mukai, R. et al. Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan. Sci. Rep. 13, 8747. https://doi.org/10.1038/s41598-023-35759-4 (2023).
doi: 10.1038/s41598-023-35759-4 pubmed: 37253802 pmcid: 10229564
Matsumoto, H., Hoshino, J., Nakamura, K., Nagashima, T. & Akiyama, H. Short-term outcomes of intravitreal faricimab for treatment-naive neovascular age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. https://doi.org/10.1007/s00417-023-06116-y (2023).
doi: 10.1007/s00417-023-06116-y pubmed: 37674073
Cheng, A. M., Joshi, S., Banoub, R. G., Saddemi, J. & Chalam, K. V. Faricimab effectively resolves intraretinal fluid and preserves vision in refractory, recalcitrant, and nonresponsive neovascular age-related macular degeneration. Cureus 15, e40100. https://doi.org/10.7759/cureus.40100 (2023).
doi: 10.7759/cureus.40100 pubmed: 37425528 pmcid: 10328548
Inoda, S. et al. Visual and anatomical outcomes after initial intravitreal faricimab injection for neovascular age-related macular degeneration in patients with prior treatment history. Ophthalmol. Ther. https://doi.org/10.1007/s40123-023-00779-w (2023).
doi: 10.1007/s40123-023-00779-w pubmed: 37531030 pmcid: 10441946
Jaffe, G. J. et al. Macular morphology and visual acuity in year five of the comparison of age-related macular degeneration treatments trials. Ophthalmology 126, 252–260. https://doi.org/10.1016/j.ophtha.2018.08.035 (2019).
doi: 10.1016/j.ophtha.2018.08.035 pubmed: 30189282
Guymer, R. H. et al. Tolerating subretinal fluid in neovascular age-related Macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results. Ophthalmology 126, 723–734. https://doi.org/10.1016/j.ophtha.2018.11.025 (2019).
doi: 10.1016/j.ophtha.2018.11.025 pubmed: 30502372
Chakravarthy, U. et al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye (Lond.) 35, 2983–2990. https://doi.org/10.1038/s41433-020-01354-4 (2021).
doi: 10.1038/s41433-020-01354-4 pubmed: 33414525
Khanani, A. M., Eichenbaum, D., Schlottmann, P. G., Tuomi, L. & Sarraf, D. Optimal management of pigment epithelial detachments in eyes with neovascular age-related macular degeneration. Retina 38, 2103–2117. https://doi.org/10.1097/iae.0000000000002195 (2018).
doi: 10.1097/iae.0000000000002195 pubmed: 29697591 pmcid: 6221406
Cheong, K. X., Teo, K. Y. C. & Cheung, C. M. G. Influence of pigment epithelial detachment on visual acuity in neovascular age-related macular degeneration. Surv. Ophthalmol. 66, 68–97. https://doi.org/10.1016/j.survophthal.2020.05.003 (2021).
doi: 10.1016/j.survophthal.2020.05.003 pubmed: 32428539
Ohji, M. et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: A randomized controlled trial. Adv. Ther. 37, 1173–1187. https://doi.org/10.1007/s12325-020-01236-x (2020).
doi: 10.1007/s12325-020-01236-x pubmed: 32016788 pmcid: 7089719
Adrean, S. D., Chaili, S., Grant, S. & Pirouz, A. Recurrence rate of choroidal neovascularization in neovascular age-related macular degeneration managed with a treat-extend-stop protocol. Ophthalmol. Retina 2, 225–230. https://doi.org/10.1016/j.oret.2017.07.009 (2018).
doi: 10.1016/j.oret.2017.07.009 pubmed: 31047590
Munk, M. R. et al. The impact of the vitreomacular interface in neovascular age-related macular degeneration in a treat-and-extend regimen with exit strategy. Ophthalmol. Retina 2, 288–294. https://doi.org/10.1016/j.oret.2017.07.010 (2018).
doi: 10.1016/j.oret.2017.07.010 pubmed: 31047237
Nguyen, V. et al. Outcomes of suspending VEGF inhibitors for neovascular age-related macular degeneration when lesions have been inactive for 3 months. Ophthalmol. Retina 3, 623–628. https://doi.org/10.1016/j.oret.2019.05.013 (2019).
doi: 10.1016/j.oret.2019.05.013 pubmed: 31281103
Hirata, Y. et al. Recurrence of neovascular age-related macular degeneration after cessation of treat and extend regimen. Sci. Rep. 12, 14768. https://doi.org/10.1038/s41598-022-19062-2 (2022).
doi: 10.1038/s41598-022-19062-2 pubmed: 36042371 pmcid: 9427844
Matsubara, H. et al. Effects of suspension of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration in clinical setting. Graefes Arch. Clin. Exp. Ophthalmol. 260, 1867–1876. https://doi.org/10.1007/s00417-021-05526-0 (2022).
doi: 10.1007/s00417-021-05526-0 pubmed: 35094126 pmcid: 9061688
Garweg, J. G. et al. Continued anti-VEGF treatment does not prevent recurrences in eyes with stable neovascular age-related macular degeneration using a treat-and-extend regimen: A retrospective case series. Eye (Lond.) 36, 862–868. https://doi.org/10.1038/s41433-021-01562-6 (2022).
doi: 10.1038/s41433-021-01562-6 pubmed: 33941877
Aslanis, S., Amrén, U., Lindberg, C. & Epstein, D. Recurrent neovascular age-related macular degeneration after discontinuation of vascular endothelial growth factor inhibitors managed in a treat-and-extend regimen. Ophthalmol. Retina 6, 15–20. https://doi.org/10.1016/j.oret.2021.03.010 (2022).
doi: 10.1016/j.oret.2021.03.010 pubmed: 33775926
Inoda, S. et al. Cytokine profiles of macular neovascularization in the elderly based on a classification from a pachychoroid/drusen perspective. Graefes Arch. Clin. Exp. Ophthalmol. 260, 747–758. https://doi.org/10.1007/s00417-021-05445-0 (2022).
doi: 10.1007/s00417-021-05445-0 pubmed: 34714383
Maruko, I., Iida, T., Saito, M., Nagayama, D. & Saito, K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am. J. Ophthalmol. 144, 15–22. https://doi.org/10.1016/j.ajo.2007.03.047 (2007).
doi: 10.1016/j.ajo.2007.03.047 pubmed: 17509509
Matsumoto, H. et al. Clinical characteristics and pachychoroid incidence in Japanese patients with neovascular age-related macular degeneration. Sci. Rep. 12, 4492. https://doi.org/10.1038/s41598-022-08666-3 (2022).
doi: 10.1038/s41598-022-08666-3 pubmed: 35296769 pmcid: 8927155
Mitchell, P., Wang, J. J., Foran, S. & Smith, W. Five-year incidence of age-related maculopathy lesions: The Blue Mountains Eye Study. Ophthalmology 109, 1092–1097. https://doi.org/10.1016/s0161-6420(02)01055-2 (2002).
doi: 10.1016/s0161-6420(02)01055-2 pubmed: 12045049
Klein, R., Klein, B. E., Tomany, S. C., Meuer, S. M. & Huang, G. H. Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study. Ophthalmology 109, 1767–1779. https://doi.org/10.1016/s0161-6420(02)01146-6 (2002).
doi: 10.1016/s0161-6420(02)01146-6 pubmed: 12359593
Mori, R. et al. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial. Jpn. J. Ophthalmol. 67, 301–310. https://doi.org/10.1007/s10384-023-00985-w (2023).
doi: 10.1007/s10384-023-00985-w pubmed: 37039948 pmcid: 10098238
Takahashi, K. et al. Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials. Graefes Arch. Clin. Exp. Ophthalmol. https://doi.org/10.1007/s00417-023-06071-8 (2023).
doi: 10.1007/s00417-023-06071-8 pubmed: 37792069 pmcid: 10844383
Kim, J. et al. Tie2 activation promotes choriocapillary regeneration for alleviating neovascular age-related macular degeneration. Sci. Adv. 5, eaau6732. https://doi.org/10.1126/sciadv.aau6732 (2019).
doi: 10.1126/sciadv.aau6732 pubmed: 30788433 pmcid: 6374104
Liu, P., Lavine, J. A., Fawzi, A., Quaggin, S. E. & Thomson, B. R. Angiopoietin-1 is required for vortex vein and choriocapillaris development in mice. Arterioscler. Thromb. Vasc. Biol. 42, 1413–1427. https://doi.org/10.1161/atvbaha.122.318151 (2022).
doi: 10.1161/atvbaha.122.318151 pubmed: 36172864 pmcid: 9613622

Auteurs

Hironori Takahashi (H)

Department of Ophthalmology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi, 329-0431, Japan.

Satoru Inoda (S)

Department of Ophthalmology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi, 329-0431, Japan. r1208is@jichi.ac.jp.

Hidenori Takahashi (H)

Department of Ophthalmology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi, 329-0431, Japan.

Ryota Takahashi (R)

Department of Ophthalmology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi, 329-0431, Japan.

Yuto Hashimoto (Y)

Department of Ophthalmology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi, 329-0431, Japan.

Hana Yoshida (H)

Department of Ophthalmology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi, 329-0431, Japan.

Hidetoshi Kawashima (H)

Department of Ophthalmology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi, 329-0431, Japan.

Yasuo Yanagi (Y)

Department of Ophthalmology and Micro-Technology, Yokohama City University, Yokohama, Japan.
Retina Research Group, Singapore Eye Research Institute, Singapore Eye-ACP, Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.

Classifications MeSH